Pharmaxis cuts manufacturing costs in face of FDA response

Australia respiratory drugmaker Pharmaxis said it will cut 48 jobs in its manufacturing and clinical areas to save $12 million after the FDA asked for additional data on its Bronchitol treatment for cystic fibrosis. That is 37% of its workforce. FierceBiotech reports that the company is taking the steps as it prepares to take another crack at a pivotal study to provide the FDA with the information it requires. While details of the cuts were few, it said it will "further downsize manufacturing" operations in Australia. The company will, however, continue to invest "long term in manufacturing capability for Bronchitol and Aridol," it said in a statement. Story | More (PDF)